Effects on anginal symptoms of sudden withdrawal of large doses of propranolol or placebo were evaluated in 20 patients in a double-blind crossover efficacy trial requiring sudden cessation of the agent. With propranolol, 160 to 320 mg per day for six and 12 weeks, no patients had increased angina or nitroglycerin use, and there were no hospitalizations or deaths. However, within two weeks of discontinuance of propranolol, untoward ischemic events developed in 10 patients. Six had serious withdrawal complications: intermediate coronary syndrome in three, and ventricular tachycardia, fatal myocardial infarction, and sudden death in one each. In four patients discontinuance of placebo increased anginal symptoms; in the remaining 10, ischemic symptoms were not provoked. The rebound phenomenon was related to degree of pre-propranolol angina and relief of pain by the agent. Thus, chronically administered propranolol should be gradually reduced, and activity restricted during its withdrawal.
Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol
Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension
Comparison of changes in the characteristics of beta-adrenoceptors and responsiveness of human circulating lymphocytes during and after chronic administration of pindolol and propranolol
The phenomenon of beta-adrenergic hypersensitivity following propranolol withdrawal studied in normal subjects
Abrupt withdrawal of beta-blocking agents in patients with arterial hypertension. Effect on blood pressure, heart rate and plasma catecholamines and prolactin
Dissociation between duration of plasma catecholamine and blood pressure responses to beta-adrenergic blockade in normotensive subjects during physical exercise
Haemodynamic, metabolic, and lymphocyte beta 2-adrenoceptor changes following chronic beta-adrenoceptor antagonism
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 4. Adverse effects. Choosing a beta-adrenoreceptor blocker
Selective lysosomal uptake and accumulation of the beta-adrenergic antagonist propranolol in cultured and isolated cell systems
Chronic treatment with nifedipine does not change the number of [3H]nitrendipine and [3H]dihydroalprenolol binding sites
Propranolol withdrawal-induced supersensitivity to the chronotropic effects of isoproterenol in the conscious rabbit
Effects of propranolol, clonidine and hydrochlorothiazide treatment and abrupt discontinuation on central and peripheral noradrenergic activity in essential hypertension
Measurement and cardiovascular relevance of partial agonist activity (PAA) involving beta 1- and beta 2-adrenoceptors
Persistent transient myocardial ischemia despite beta-adrenergic blockade predicts a higher risk of adverse cardiac events in patients with coronary artery disease
Symptom-limited exercise combined with dipyridamole stress: prognostic value in assessment of known or suspected coronary artery disease by use of gated SPECT imaging
Reduction in dipyridamole-induced single-photon emission computed tomography myocardial defect size by beta-blockers: time to re-examine the patient preparation protocol for pharmacologic stress testing
Do beta-blockers affect the diagnostic sensitivity of dobutamine stress thallium-201 single photon emission computed tomographic imaging?
Rebound hemodynamic events after the abrupt withdrawal of nitroprusside in patients with severe chronic heart failure
Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction
Intravenous beta-blockade in coronary heart disease: is cardioselectivity or intrinsic sympathomimetic activity hemodynamically useful?
Hemodynamic responses and long-term follow-up results in patients using chronic beta 1-selective and nonselective beta-blockers during dobutamine stress echocardiography
Does beta blocker therapy affect the diagnostic accuracy of adenosine single-photon-emission computed tomographic myocardial perfusion imaging?
Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor
The use of dobutamine in myocardial infarction for reversal of the cardiodepressive effect of metoprolol
Home blood pressure monitoring and changes in plasma catecholamines during once or twice daily treatment with atenolol in patients with mild hypertension
Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study
Comparison of atenolol with propranolol in the treatment of angina pectoris with special reference to once daily administration of atenolol
Haemodynamic effects of a new beta 1-receptor agonist in acute myocardial infarction. A useful antidote to unwanted cardiac effects of beta-blocking agents
Effects of coronary artery bypass grafting on left ventricular function assessed by multiple gated ventricular scintigraphy
Abrupt withdrawal of atenolol in patients with severe angina. Comparison with the effects of treatment
Does left ventricular aneurysmectomy improve ventricular function in patients undergoing coronary bypass surgery?
Abrupt withdrawal of atenolol in patients with severe angina: comparison with the effects of treatment
Beta adrenergic receptor blockade of feline myocardium. Cardiac mechanics, energetics, and beta adrenoceptor regulation
ß-adrenoceptor blockers increase cardiac sympathetic innervation by inhibiting autoreceptor suppression of axon growth
Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization
Shortened platelet survival time and enhanced heart rate responses after abrupt withdrawal of propranolol from normal subjects
Comparison of hypersensitivity to adrenergic stimulation after abrupt withdrawal of propranolol and nadolol: influence of half-life differences
First ultra-short-acting beta-adrenergic blocking agent: its effect on size and segmental wall dynamics of reperfused myocardial infarcts in dogs
Chronic administration of nifedipine induces up-regulation of functional calcium channels in rat myocardium
Comparison of the β-Adrenergic Receptor Antagonists Landiolol and Esmolol: Receptor Selectivity, Partial Agonism, and Pharmacochaperoning Actions
Risk of acute myocardial infarction after discontinuation of antihypertensive agents: a case-control study
Cardiopulmonary bypass alters the pharmacokinetics of propranolol in patients undergoing cardiac surgery
Radionuclide assessment of ventricular performance during propranolol withdrawal prior to aortocoronary bypass surgery
Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina
Comparison of five beta-adrenoreceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris
Relax, Cool Down and Scaffold: How to Restore Surface Expression of Folding-Deficient Mutant GPCRs and SLC6 Transporters
Abrupt withdrawal of beta-blockade therapy in patients with myocardial infarction: effects on infarct size, left ventricular function, and hospital course
Adrenergic responsiveness after abrupt propranolol withdrawal in normal subjects and in patients with angina pectoris
Glucose metabolism during ischemia due to excessive oxygen demand or altered coronary flow in the isolated arterially perfused rabbit septum
Nifedipine reduces the incidence of myocardial infarction and transient ischemia in patients undergoing coronary bypass grafting
Lack of beta-adrenoreceptor hypersensitivity after abrupt withdrawal of long-term therapy with oxprenolol
Perioperative beta-blockade, discontinuation, and complications: do you really know it when you see it?
Long-term beta-receptor blockade--adrenergic and metabolic response to surgery and neurolept anaesthesia
Chaperoning of the A1-adenosine receptor by endogenous adenosine - an extension of the retaliatory metabolite concept
Effects of Preoperative β-Blocker Use on Clinical Outcomes after Coronary Artery Bypass Grafting: A Report from the Japanese Cardiovascular Surgery Database
Acute myocardial infarction caused by multivessel coronary spasm due to calcium channel blocker withdrawal
Beta-adrenoceptor blockade and anaesthesia. Beta-adrenoceptor antagonism during anaesthesia for coronary artery surgery
Beta-adrenergic blockade and anaesthesia with reference to interactions with anaesthetic drugs and techniques
Perioperative myocardial injury and infarction following non-cardiac surgery: A review of the eclipsed epidemic
Speed of onset of pharmacodynamic activity of propranolol, practolol, oxprenolol and metoprolol after intravenous infection in man
Patient compliance and therapeutic coverage: amlodipine versus nifedipine (slow-release) in the treatment of angina pectoris. Belgian Collaborative Group
Lack of clinical or haemodynamic rebound after abrupt interruption of beta-blockers in patients with cirrhosis
Effects of 6 Months of Exercise-Based Cardiac Rehabilitation on Autonomic Function and Neuro-Cardiovascular Stress Reactivity in Coronary Artery Disease Patients
Penbutolol or hydrochlorothiazide once a day in hypertension. A controlled study with home measurements
Beta blocker rebound phenomenon is important, but we do not know its definition, incidence or optimal prevention strategies.
Antianginal Drugs: Mechanisms of Action
Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.
Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.